Last reviewed · How we verify
Isoglycemic Clamp
Isoglycemic Clamp is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Merck Sharp & Dohme LLC is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Isoglycemic Clamp |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes
- Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle (NA)
- Insulin Modulation of fMRI Connectivity in Healthy Adults (EARLY_PHASE1)
- Exercise, Glucose Kinetics, and the Incretin Effect (NA)
- Investigating the Incretin Effect in Cystic Fibrosis
- Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168) (PHASE1)
- Incretin Physiology and Beta-cell Function Before and After Weight-loss
- n-3 Fatty Acid Infusion and Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isoglycemic Clamp CI brief — competitive landscape report
- Isoglycemic Clamp updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Isoglycemic Clamp
What is Isoglycemic Clamp?
Who makes Isoglycemic Clamp?
What development phase is Isoglycemic Clamp in?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing